NO20022649D0 - Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer - Google Patents

Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer

Info

Publication number: NO20022649D0
Authority: NO; Norway
Prior art keywords: dihydropyrimidines; heterocyclic; potassium channel; channel inhibitors; inhibitors
Prior art date: 1999-12-06

Application number

NO20022649A

Other languages

English (en)

Other versions

NO20022649L (no

NO323588B1 (no

Inventor

Karnail S Atwal

Wayne D Vaccaro

John Lloyd

Heather Finlay

Lin Yan

Rao S Bhandaru

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-06

Filing date

2002-06-05

Publication date

2002-06-05

2002-06-05 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2002-06-05 Publication of NO20022649D0 publication Critical patent/NO20022649D0/no

2002-06-06 Publication of NO20022649L publication Critical patent/NO20022649L/no

2007-06-11 Publication of NO323588B1 publication Critical patent/NO323588B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Diabetes (AREA)
Immunology (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)

NO20022649A 1999-12-06 2002-06-05 Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer samt anvendelse derav og farmasoytisk preparat. NO323588B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US16909199P	1999-12-06	1999-12-06
US23603700P	2000-09-28	2000-09-28
PCT/US2000/032785 WO2001040231A1 (en)	1999-12-06	2000-12-04	Heterocyclic dihydropyrimidines as potassium channel inhibitors

Publications (3)

Publication Number	Publication Date
NO20022649D0 true NO20022649D0 (no)	2002-06-05
NO20022649L NO20022649L (no)	2002-06-06
NO323588B1 NO323588B1 (no)	2007-06-11

Family

ID=26864749

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20022649A NO323588B1 (no)	1999-12-06	2002-06-05	Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer samt anvendelse derav og farmasoytisk preparat.

Country Status (25)

Country	Link
US (3)	US6706720B2 (no)
EP (1)	EP1237891B1 (no)
JP (1)	JP2004507442A (no)
KR (1)	KR20020060255A (no)
CN (1)	CN1407985A (no)
AR (1)	AR029457A1 (no)
AT (1)	ATE526329T1 (no)
AU (1)	AU781862B2 (no)
BR (1)	BR0016166A (no)
CA (1)	CA2393809C (no)
CO (1)	CO5570109A1 (no)
CZ (1)	CZ20021949A3 (no)
HK (1)	HK1048808A1 (no)
HU (1)	HUP0301834A3 (no)
IL (2)	IL149473A0 (no)
MX (1)	MXPA02005533A (no)
MY (1)	MY125533A (no)
NO (1)	NO323588B1 (no)
NZ (1)	NZ518663A (no)
PE (1)	PE20011029A1 (no)
PL (1)	PL364926A1 (no)
RU (1)	RU2296766C2 (no)
TW (1)	TWI291465B (no)
UY (1)	UY26472A1 (no)
WO (1)	WO2001040231A1 (no)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9901691D0 (en)	1999-01-26	1999-03-17	Cerebrus Ltd	Chemical compounds
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
PL360027A1 (en) *	2000-06-30	2004-09-06	Wyeth	Substituted-triazolopyrimidines as anticancer agents
PT1350511E (pt) *	2000-12-25	2008-10-28	Ube Industries	Composições medicinais contendo aspirina
TWI243164B (en)	2001-02-13	2005-11-11	Aventis Pharma Gmbh	Acylated indanyl amines and their use as pharmaceuticals
EP1435955A2 (en) *	2001-05-05	2004-07-14	SmithKline Beecham P.L.C.	N-aroyl cyclic amine derivatives as orexin receptor antagonists
AR033306A1 (es)	2001-05-05	2003-12-10	Smithkline Beecham Plc	Compuestos
US7139344B2 (en) *	2001-05-16	2006-11-21	Lexmark International, Inc.	Method and apparatus for effecting synchronous pulse generation for use in variable speed serial communications
MXPA03011706A (es) *	2001-06-28	2004-03-19	Smithkline Beecham Plc	Derivados de n-aroil-amina ciclica como antagonistas del receptor de orexina.
GB0115862D0 (en) *	2001-06-28	2001-08-22	Smithkline Beecham Plc	Compounds
UA78232C2 (uk)	2001-09-21	2007-03-15	Брістол-Майерс Сквібб Компані	Лактамвмісні сполуки та їх похідні як інгібітори фактора ха
ATE541847T1 (de) *	2001-11-01	2012-02-15	Icagen Inc	Pyrazolopyrimidine als natriumkanalblocker
US7435824B2 (en)	2002-04-19	2008-10-14	Bristol-Myers Squibb Company	Prodrugs of potassium channel inhibitors
WO2003101993A1 (en) *	2002-06-04	2003-12-11	Neogenesis Pharmaceuticals, Inc.	Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
WO2004071440A2 (en)	2003-02-06	2004-08-26	Bristol-Myers Squibb Company	Thiazolyl-based compounds useful as kinase inhibitors
US6846836B2 (en)	2003-04-18	2005-01-25	Bristol-Myers Squibb Company	N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
ATE482200T1 (de)	2003-05-01	2010-10-15	Bristol Myers Squibb Co	Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
GB0315950D0 (en)	2003-06-11	2003-08-13	Xention Discovery Ltd	Compounds
US20050187278A1 (en) *	2003-08-28	2005-08-25	Pharmacia Corporation	Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
EP1677791A4 (en) *	2003-10-31	2007-08-15	Takeda Pharmaceutical	NITROGENIC CONDENSED HETEROCYCLIC COMPOUNDS
RU2256450C1 (ru) *	2004-03-04	2005-07-20	Лазебник Леонид Борисович	Способ лечения фибрилляции предсердий
US7550499B2 (en)	2004-05-12	2009-06-23	Bristol-Myers Squibb Company	Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1750862B1 (en) *	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition containing irbesartan
GB0412986D0 (en)	2004-06-10	2004-07-14	Xention Discovery Ltd	Compounds
US7253167B2 (en) *	2004-06-30	2007-08-07	Bristol-Myers Squibb Company	Tricyclic-heteroaryl compounds useful as kinase inhibitors
US7754755B2 (en) *	2004-09-23	2010-07-13	Bristol-Myers Squibb Company	Inhibitors of 15-lipoxygenase
US7429611B2 (en) *	2004-09-23	2008-09-30	Bristol-Myers Squibb Company	Indole inhibitors of 15-lipoxygenase
US20060128726A1 (en) *	2004-11-24	2006-06-15	Xuebao Wang	Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
US7576212B2 (en)	2004-12-09	2009-08-18	Xention Limited	Thieno[2,3-B] pyridines as potassium channel inhibitors
CN101137412B (zh)	2005-01-13	2012-11-07	布里斯托尔-迈尔斯·斯奎布公司	用作凝血因子XIa抑制剂的取代的二芳基化合物
WO2006078621A2 (en)	2005-01-19	2006-07-27	Bristol-Myers Squibb Company	2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
US20060178388A1 (en) *	2005-02-04	2006-08-10	Wrobleski Stephen T	Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
WO2006133261A2 (en)	2005-06-06	2006-12-14	Intra-Cellular Therapies, Inc.	Organic compounds
US7700620B2 (en)	2005-06-27	2010-04-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US7728008B2 (en)	2005-06-27	2010-06-01	Bristol-Myers Squibb Company	N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
WO2007002634A1 (en)	2005-06-27	2007-01-04	Bristol-Myers Squibb Company	Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
ES2360818T3 (es)	2005-06-27	2011-06-09	Bristol-Myers Squibb Company	Miméticos de urea lineal antagonistas del receptor p2y, útiles en el tratamiento de afecciones trombóticas.
US7473784B2 (en) *	2005-08-01	2009-01-06	Bristol-Myers Squibb Company	Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
JP2009504638A (ja) *	2005-08-08	2009-02-05	アストラゼネカ・アクチエボラーグ	治療薬
US7534804B2 (en) *	2005-08-24	2009-05-19	Bristol-Myers Squibb Company	Benzoxazole inhibitors of 15-lipoxygenase
WO2007027454A1 (en)	2005-08-30	2007-03-08	Bristol-Myers Squibb Company	Heterocyclic dihydropyrimidine compounds
ES2273599B1 (es) *	2005-10-14	2008-06-01	Universidad De Barcelona	Compuestos para el tratamiento de la fibrilacion auricular.
GB0525164D0 (en)	2005-12-09	2006-01-18	Xention Discovery Ltd	Compounds
AU2007210013B2 (en) *	2006-02-01	2011-08-18	Merck Sharp & Dohme Corp.	Potassium channel inhibitors
EP2023729B1 (en)	2006-06-06	2016-05-04	Intra-Cellular Therapies, Inc.	Organic compounds
CA2654262A1 (en) *	2006-06-20	2007-12-27	Wyeth	Kv1.5 potassium channel inhibitors
TW200812962A (en) *	2006-07-12	2008-03-16	Astrazeneca Ab	New compounds I/418
WO2009010810A2 (en) *	2006-08-07	2009-01-22	Wockhardt Limited	Cardiovascular combinations comprising ace and hmg-co-a inhibitors
US7960569B2 (en)	2006-10-17	2011-06-14	Bristol-Myers Squibb Company	Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP2089034A4 (en)	2006-12-05	2010-07-28	Intra Cellular Therapies Inc	NEW USES
CN101663293B (zh)	2007-04-23	2013-07-31	塞诺菲-安万特股份有限公司	作为p2y12拮抗剂的喹啉-甲酰胺衍生物
MX2009011755A (es)	2007-05-02	2010-02-12	Portola Pharm Inc	Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas.
WO2009006580A1 (en) *	2007-07-05	2009-01-08	Cv Therapeutics, Inc.	Optionally condensed dihydropyridine, dihydropyrimidine and dihydropyrane derivatives acting as late sodium channel blockers
US20090012103A1 (en) *	2007-07-05	2009-01-08	Matthew Abelman	Substituted heterocyclic compounds
US8431608B2 (en)	2007-08-17	2013-04-30	Icagen Inc.	Heterocycles as potassium channel modulators
CN101842011A (zh) *	2007-08-17	2010-09-22	安克进药物公司	作为钾通道调节剂的杂环
AU2008331833A1 (en) *	2007-12-06	2009-06-11	Intra-Cellular Therapies, Inc	Organic compounds
BRPI0820698A2 (pt) *	2007-12-19	2019-09-24	Wyeth Llc	4-imidazolidinonas como inibidores de canal de potássio kv1.5
CA2709187A1 (en) *	2007-12-19	2009-06-25	Wyeth Llc	4-imidazolidinones as kv1.5 potassium channel inhibitors
CN101903356B (zh)	2007-12-20	2013-05-22	拜耳知识产权有限责任公司	4-(4-氰基-2-硫代芳基)二氢嘧啶酮和它们的使用
JP5504171B2 (ja)	2007-12-26	2014-05-28	サノフイ	Ｐ２ｙ１２アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
EP2300435A2 (en)	2008-05-19	2011-03-30	Schering Corporation	Heterocyclic compounds as factor ixa inhibitors
RU2376307C1 (ru) *	2008-05-27	2009-12-20	Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук	4-((Z)-4'-ГИДРОКСИБУТЕН-2'-ИЛ)-2-R-6-ФЕНИЛ-1,2,4-ТРИАЗОЛО[5,1-c][1,2,4]ТРИАЗИН-7-ОНЫ
GB2461037A (en) *	2008-06-17	2009-12-23	Elias Bouras	A method of treating alopecia using a composition comprising a cardiac glycoside
RU2463070C1 (ru) *	2008-07-23	2012-10-10	Хэбэй Илин Медицин Рисёч Инститьют Ко., Лтд.	Фармацевтическая композиция для регуляции калиевых каналов в клетке сердечной мышцы, способ ее получения и ее применения
GB0815781D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
GB0815784D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
GB0815782D0 (en)	2008-08-29	2008-10-08	Xention Ltd	Novel potassium channel blockers
MX2011005933A (es)	2008-12-06	2011-12-16	Intra Cellular Therapies Inc	Compuestos organicos.
GEP20146046B (en)	2008-12-06	2014-02-25	Intracellular Therapies Inc	Organic compounds
EA201170771A1 (ru) *	2008-12-06	2012-01-30	Интра-Селлулар Терапиз, Инк.	Органические соединения
BRPI0922700A2 (pt)	2008-12-06	2015-08-11	Intracellular Therapies Inc	Compostos orgânicos
WO2010065147A1 (en)	2008-12-06	2010-06-10	Intra-Cellular Therapies, Inc.	Organic compounds
EA201170769A1 (ru) *	2008-12-06	2012-02-28	Интра-Селлулар Терапиз, Инк.	Органические соединения
DE102009004197A1 (de)	2009-01-09	2010-07-15	Bayer Schering Pharma Aktiengesellschaft	Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
WO2010132127A1 (en)	2009-05-13	2010-11-18	Intra-Cellular Therapies, Inc.	Organic compounds
GB0909672D0 (en)	2009-06-04	2009-07-22	Xention Discovery Ltd	Compounds
GB0909671D0 (en)	2009-06-04	2009-07-22	Xention Discovery Ltd	Compounds
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
JP5663571B2 (ja) *	2009-07-02	2015-02-04	サノフイ	新規２，３−ジヒドロ−１Ｈ−イミダゾ｛１，２−ａ｝ピリミジン−５−オン誘導体、これらの調製およびこれらの薬学的使用
RU2561130C2 (ru) *	2009-07-02	2015-08-20	Санофи	НОВЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОПИРИМИДО{1,2-a}ПИРИМИДИН-6-ОНА, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ
WO2011017296A1 (en)	2009-08-04	2011-02-10	Schering Corporation	4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
US9434730B2 (en)	2010-05-31	2016-09-06	Intra-Cellular Therapies, Inc.	PDE1 inhibitor compounds
EP2576551A4 (en)	2010-05-31	2014-04-16	Intra Cellular Therapies Inc	ORGANIC CONNECTIONS
WO2011153135A1 (en)	2010-05-31	2011-12-08	Intra-Cellular Therapies, Inc.	Organic compounds
TW201206937A (en)	2010-05-31	2012-02-16	Intra Cellular Therapies Inc	Organic compounds
WO2012067822A1 (en) *	2010-11-16	2012-05-24	Abbott Laboratories	Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators
BR112013018515B1 (pt) *	2011-01-26	2021-06-29	Nerviano Medical Sciences S.R.I	Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
GB201105659D0 (en)	2011-04-01	2011-05-18	Xention Ltd	Compounds
US8859549B2 (en)	2011-05-13	2014-10-14	Abbvie, Inc.	Potassium channel modulators
EP2717877B1 (en)	2011-06-10	2017-11-08	Intra-Cellular Therapies, Inc.	Organic compounds
US9309250B2 (en)	2011-06-22	2016-04-12	Vertex Pharmaceuticals Incorporated	Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
NO3175985T3 (no)	2011-07-01	2018-04-28
CN103917529B (zh)	2011-11-11	2016-08-17	辉瑞大药厂	2-硫代嘧啶酮类
EP2806865A1 (en)	2012-01-27	2014-12-03	Gilead Sciences, Inc.	Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
WO2013130808A1 (en)	2012-02-29	2013-09-06	D.E. Shaw Research, Llc	Methods for screening voltage gated proteins
AP2014007953A0 (en)	2012-04-06	2014-09-30	Pfizer	Diacylglycerol acyltransferase 2 inhibitors
US9333202B2 (en)	2012-05-01	2016-05-10	The Trustees Of Columbia University In The City Of New York	Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
HRP20180859T1 (hr)	2012-12-07	2018-07-13	Vertex Pharmaceuticals Incorporated	2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid kao inhibitor atr kinaze
EP2956141A4 (en)	2013-02-17	2016-10-26	Intra Cellular Therapies Inc	NEW USES
WO2014152018A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydrocyclopentapyrroles, their preparation and use
ES2705247T3 (es)	2013-03-14	2019-03-22	Univ Columbia	4-fenilpiperidinas, su preparación y uso
WO2014151959A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	N-alkyl-2-phenoxyethanamines, their preparation and use
WO2014151936A1 (en)	2013-03-14	2014-09-25	The Trustees Of Columbia University In The City Of New York	Octahydropyrrolopyrroles, their preparation and use
EP2970288A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of atr kinase
EP2970286A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP3479825B1 (en)	2013-03-15	2021-02-17	Intra-Cellular Therapies, Inc.	Pde1 inhibitors for use in the treatment and/or prevention of cns or pns diseases or disorders
JP2016512239A (ja)	2013-03-15	2016-04-25	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Ａｔｒキナーゼの阻害剤として有用な化合物
AU2014234990B2 (en)	2013-03-15	2017-11-16	Intra-Cellular Therapies, Inc.	Organic compounds
JP6348582B2 (ja)	2013-10-09	2018-06-27	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
RU2537295C1 (ru) *	2013-11-01	2014-12-27	Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий"	4-(2-ГИДРОКСИЭТОКСИ)МЕТИЛ)-5-МЕТИЛ-2-МЕТИЛМЕРКАПТО-1,2,4-ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7(4Н)-ОН - ВЕЩЕСТВО, ОБЛАДАЮЩЕЕ ПРОТИВОВИРУСНЫМ ДЕЙСТВИЕМ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ ПРОТИВ ВОЗБУДИТЕЛЯ ЛИХОРАДКИ ЗАПАДНОГО НИЛА
HRP20192183T1 (hr)	2013-12-06	2020-02-21	Vertex Pharmaceuticals Inc.	Spoj 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida koristan kao inhibitor atr kinase, njegova priprava, različiti kruti oblici te njegovi radioaktivno označeni derivati
SI3119757T1 (en)	2014-03-17	2018-08-31	Pfizer Inc.	Diacylglycerol acyltransferase 2 inhibitors for use in the treatment of metabolic and related disorders
RS58597B1 (sr)	2014-04-04	2019-05-31	Pfizer	Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
WO2015160636A1 (en)	2014-04-16	2015-10-22	Merck Sharp & Dohme Corp.	Factor ixa inhibitors
CN111393434B (zh) *	2014-04-30	2022-11-04	哥伦比亚大学董事会	取代的4-苯基哌啶及其制备和用途
EP3152212B9 (en)	2014-06-05	2020-05-27	Vertex Pharmaceuticals Inc.	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
EP3157566B1 (en)	2014-06-17	2019-05-01	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of chk1 and atr inhibitors
WO2015196186A1 (en)	2014-06-20	2015-12-23	Intra-Cellular Therapies, Inc.	Organic compounds
US10131671B2 (en)	2014-08-07	2018-11-20	Intra-Cellular Therapies, Inc.	Organic compounds
US9546175B2 (en)	2014-08-07	2017-01-17	Intra-Cellular Therapies, Inc.	Organic compounds
US10285992B2 (en)	2014-08-07	2019-05-14	Intra-Cellular Therapies, Inc.	Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
RU2711442C2 (ru)	2014-09-17	2020-01-17	Интра-Селлулар Терапиз, Инк.	Соединения и способы
JP2017538769A (ja)	2014-12-22	2017-12-28	ファイザー・インク	プロスタグランジンｅｐ３受容体の拮抗薬
CA2980071A1 (en)	2015-03-18	2016-09-22	Bayer Pharma Aktiengesellschaft	Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
MA42035A (fr)	2015-05-05	2018-03-14	Pfizer	2-thiopyrimidinones
CA2987179C (en)	2015-05-29	2020-08-25	Pfizer Inc.	Heterocyclic compounds as inhibitors of vanin-1 enzyme
PL3310784T3 (pl)	2015-06-17	2021-03-08	Pfizer Inc.	Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
WO2016203335A1 (en)	2015-06-18	2016-12-22	Pfizer Inc.	Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
JP2018527337A (ja)	2015-08-13	2018-09-20	ファイザー・インク	二環式縮合ヘテロアリールまたはアリール化合物
ES2865199T3 (es)	2015-08-27	2021-10-15	Pfizer	Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
WO2017037567A1 (en)	2015-09-03	2017-03-09	Pfizer Inc.	Regulators of frataxin
HK1258570A1 (zh)	2015-09-30	2019-11-15	Vertex Pharmaceuticals Inc.	使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
DK3397631T3 (da)	2015-12-29	2021-05-25	Pfizer	Substituerede 3-azabicyclo[3.1.0]hexaner som ketohexokinase-inhibitorer
US10682354B2 (en)	2016-03-28	2020-06-16	Intra-Cellular Therapies, Inc.	Compositions and methods
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
WO2017178416A1 (en) *	2016-04-15	2017-10-19	Bayer Animal Health Gmbh	Pyrazolopyrimidine derivatives
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
AU2017296338A1 (en)	2016-07-14	2019-01-03	Pfizer Inc.	Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
AR109179A1 (es)	2016-08-19	2018-11-07	Pfizer	Inhibidores de diacilglicerol aciltransferasa 2
US11291666B2 (en)	2016-09-12	2022-04-05	Intra-Cellular Therapies, Inc.	Uses
AR110401A1 (es) *	2016-12-21	2019-03-27	Chiesi Farm Spa	Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa
JOP20190284A1 (ar) *	2017-06-14	2019-12-11	Bayer Pharma AG	مركبات إيميدازوبيريميدين مستبدلة بديازا ثنائي الحلقة واستخدامها للمعالجة من اضطرابات التنفس
WO2019133445A1 (en)	2017-12-28	2019-07-04	Inception Ibd, Inc.	Aminothiazoles as inhibitors of vanin-1
EP3746081A4 (en)	2018-01-31	2021-10-27	Intra-Cellular Therapies, Inc.	Novel uses
US11254660B2 (en)	2018-08-31	2022-02-22	Pfizer Inc.	Combinations for treatment of NASH/NAFLD and related diseases
WO2020102575A1 (en)	2018-11-16	2020-05-22	Inception Ibd, Inc.	Heterocyclic aminothiazoles and uses thereof
EP3972596B1 (en)	2019-05-20	2025-07-16	Pfizer Inc.	Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
CN110229161A (zh) *	2019-07-12	2019-09-13	江苏建筑职业技术学院	四氮唑并[1,5-a]嘧啶衍生物的溶剂热合成法
US12410175B2 (en)	2019-09-03	2025-09-09	Intra-Cellular Therapies, Inc.	Compounds
US12364695B2 (en)	2020-06-02	2025-07-22	Intra-Cellular Therapies, Inc.	Methods of treating inflammatory disease
CA3189771A1 (en)	2020-07-22	2022-01-27	Janssen Pharmaceutica Nv	Compounds useful as factor xia inhibitors
US11814364B2 (en)	2021-03-18	2023-11-14	Janssen Pharmaceutica Nv	Pyridine N-oxide derivatives useful as factor XIa inhibitors
US11845748B2 (en)	2021-03-18	2023-12-19	Janssen Pharmaceutica Nv	Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
US11919881B2 (en)	2021-03-18	2024-03-05	Janssen Pharmaceutica Nv	Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
CA3214112A1 (en) *	2021-03-30	2022-10-06	Fabrizio Giordanetto	Aryl heterocyclic compounds as kv1.3 potassium shaker channel blockers
US11897880B2 (en)	2021-04-30	2024-02-13	Janssen Pharmaceutica Nv	7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
US11958856B2 (en)	2021-07-22	2024-04-16	Janssen Pharmaceutica Nv	Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
US12286429B2 (en)	2021-07-22	2025-04-29	Janssen Pharmaceutica Nv	5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors
WO2023026180A1 (en)	2021-08-26	2023-03-02	Pfizer Inc.	Amorphous form of (s)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-n-(tetrahydrofuran-3- yl)pyrimidine-5-carboxamide
TW202400166A (zh) *	2022-04-20	2024-01-01	南韓商日東製藥股份有限公司	製備用於cftr活化劑之化合物的方法及其中所使用的中間體
WO2024118524A1 (en)	2022-11-28	2024-06-06	Cerevel Therapeutics, Llc	Azaindole compounds and their use as phosphodiesterase inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL262366A (no) *	1960-03-14
GB1031088A (en) *	1964-04-16	1966-05-25	Hoechst Ag	Benzenesulphonyl-ureas and process for their manufacture
US3423414A (en)	1966-01-13	1969-01-21	Ciba Geigy Corp	Pyrazolopyridines
HU173438B (hu)	1975-11-27	1979-05-28	Chinoin Gyogyszer Es Vegyeszet	Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
BE863525A (fr)	1977-02-14	1978-07-31	Bristol Myers Co	Heterocyclopyrimidines
CA1095906A (en) *	1977-02-14	1981-02-17	Davis L. Temple, Jr.	Heterocyclopyrimidines, compositions and therapeutic process
AU557300B2 (en)	1982-03-16	1986-12-18	Farmitalia Carlo Erba S.P.A.	Substituted 1h-pyrazolo(1,5-alpha)pyrimidines and processes for their preparation
JPS59116243A (ja)	1982-12-23	1984-07-05	Mitsui Toatsu Chem Inc	２―アリールエチルエーテル誘導体およびチオエーテル誘導体の製造方法
EP0125204A1 (de) *	1983-04-12	1984-11-14	Ciba-Geigy Ag	3-Phenoxybenzyl-(2-phenyl-2,2-alkylen-äthyl)-äther und -thioäther, Verfahren zu ihrer Herstellung und ihre Verwendung in der Schädlingsbekämpfung
JPS60246387A (ja)	1984-05-22	1985-12-06	Yoshitomi Pharmaceut Ind Ltd	ジヒドロイミダゾ〔１，２−ａ〕ピリミジン誘導体
JPS60193990A (ja)	1984-03-12	1985-10-02	Yoshitomi Pharmaceut Ind Ltd	新規なポリアザ複素環誘導体
US4918074A (en) *	1984-03-12	1990-04-17	Yoshitomi Pharmaceutical Industries, Ltd.	Polyazaheterocycle compounds
JPS61227584A (ja)	1985-03-15	1986-10-09	Yoshitomi Pharmaceut Ind Ltd	ポリアザ複素環誘導体
EP0217142A3 (en) *	1985-09-30	1988-01-07	Yoshitomi Pharmaceutical Industries, Ltd.	A polyazaheterocyclic compound
US4755594A (en) *	1986-01-31	1988-07-05	Warner-Lambert Company	N6 -substituted adenosines
US4746656A (en)	1986-07-21	1988-05-24	E. R. Squibb & Sons, Inc.	1,2,4,7-tetrahydro-2-oxopyrazolo[1,5-a]pyrimidine derivatives
JPS6360985A (ja)	1986-08-08	1988-03-17	Yoshitomi Pharmaceut Ind Ltd	４，７−ジヒドロピラゾロ〔１，５−ａ〕ピリミジン誘導体
JPS63107983A (ja)	1986-09-25	1988-05-12	Yoshitomi Pharmaceut Ind Ltd	トリアゾロピリミジン誘導体
JPS63243029A (ja) *	1987-03-30	1988-10-07	Yoshitomi Pharmaceut Ind Ltd	循環器系疾患治療薬
DE3724366A1 (de) *	1987-07-23	1989-02-02	Hoechst Ag	Benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
US4950585A (en)	1987-08-18	1990-08-21	Konica Corporation	Coupler for photographic use
JPH01271751A (ja)	1988-04-23	1989-10-30	Konica Corp	新規な写真用カプラーを含有するハロゲン化銀カラー写真感光材料
GB8905130D0 (en)	1989-03-07	1989-04-19	Pfizer Ltd	Therapeutic agents
DE3922232A1 (de) *	1989-07-06	1991-01-17	Basf Ag	Fungizide guanidine
WO1993014083A1 (en)	1992-01-09	1993-07-22	Janssen Pharmaceutica N.V.	Pharmaceutically active substituted benzimidazole derivatives
JPH05289267A (ja)	1992-04-07	1993-11-05	Fuji Photo Film Co Ltd	ハロゲン化銀カラー写真感光材料
US5612359A (en) *	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
US5900415A (en) *	1994-11-07	1999-05-04	Pfizer Inc.	Certain substituted benzylamine derivatives; a new class of neuropeptide Y1 specific ligands
DE4443891A1 (de) *	1994-12-09	1996-06-13	Bayer Ag	Heterocyclisch substituierte Oxy-phenyl-(phenyl)glycinolamide
GB9500691D0 (en) *	1995-01-13	1995-03-08	Smithkline Beecham Plc	Compounds
US5670504A (en) *	1995-02-23	1997-09-23	Merck & Co. Inc.	2,6-diaryl pyridazinones with immunosuppressant activity
JPH08301871A (ja) *	1995-05-01	1996-11-19	Takeda Chem Ind Ltd	縮合複素環化合物およびその製造法
US5631282A (en) *	1995-06-07	1997-05-20	Merck & Co., Inc.	Triterpenes
US5696156A (en) *	1995-10-31	1997-12-09	Merck & Co. Inc.	Triterpene derivatives with immunosuppressant activity
US5679705A (en) *	1995-10-31	1997-10-21	Merck & Co., Inc.	Triterpene derivatives with immunosuppressant activity
FR2746309B1 (fr)	1996-03-22	1998-04-17	Oreal	Composition de teinture des fibres keratiniques contenant des pyrazolopyrimidineoxo ; leur utilisation pour la teinture comme coupleurs, procedes de teinture
US5969017A (en)	1996-10-31	1999-10-19	Merck & Co., Inc.	Methods of treating or preventing cardiac arrhythmia
US5935945A (en)	1996-10-31	1999-08-10	Merck & Co., Inc.	Methods of treating or preventing cardiac arrhythmia
TW536540B (en) *	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
JP2894445B2 (ja)	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
US5952363A (en) *	1997-03-04	1999-09-14	Novo Nordisk A/S	Pyrrolidine compounds useful in the treatment of diabetes
US6455550B1 (en) *	1997-08-22	2002-09-24	Hoffmann-La Roche Inc.	N-alkanoylphenylalanine derivatives
CN1149196C (zh)	1998-07-06	2004-05-12	布里斯托尔-迈尔斯斯奎布公司	作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
WO2000012077A1 (en)	1998-09-01	2000-03-09	Bristol-Myers Squibb Company	Potassium channel inhibitors and method
US6632836B1 (en) *	1998-10-30	2003-10-14	Merck & Co., Inc.	Carbocyclic potassium channel inhibitors
JP3583314B2 (ja) *	1999-06-17	2004-11-04	矢崎総業株式会社	端子構造
MY125533A (en) *	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
GB0012214D0 (en) *	2000-05-19	2000-07-12	Merck Sharp & Dohme	Therapeutic agents
DE10030375A1 (de) *	2000-06-21	2002-01-03	Bayer Ag	Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
JP5010089B2 (ja)	2000-09-19	2012-08-29	スピロジェンリミテッド	Ｃｃ−１０６５およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法
GB0114867D0 (en) *	2001-06-18	2001-08-08	Merck Sharp & Dohme	Therapeutic agents
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function

2000
- 2000-11-21 MY MYPI20005460A patent/MY125533A/en unknown
- 2000-11-29 TW TW089125386A patent/TWI291465B/zh not_active IP Right Cessation
- 2000-12-04 AU AU18127/01A patent/AU781862B2/en not_active Ceased
- 2000-12-04 BR BR0016166-7A patent/BR0016166A/pt not_active Application Discontinuation
- 2000-12-04 NZ NZ518663A patent/NZ518663A/en unknown
- 2000-12-04 CZ CZ20021949A patent/CZ20021949A3/cs unknown
- 2000-12-04 RU RU2002118622/04A patent/RU2296766C2/ru not_active IP Right Cessation
- 2000-12-04 WO PCT/US2000/032785 patent/WO2001040231A1/en not_active Ceased
- 2000-12-04 PL PL00364926A patent/PL364926A1/xx not_active Application Discontinuation
- 2000-12-04 AT AT00980930T patent/ATE526329T1/de not_active IP Right Cessation
- 2000-12-04 CN CN00816751A patent/CN1407985A/zh active Pending
- 2000-12-04 HK HK03100853.3A patent/HK1048808A1/zh unknown
- 2000-12-04 HU HU0301834A patent/HUP0301834A3/hu unknown
- 2000-12-04 KR KR1020027007194A patent/KR20020060255A/ko not_active Ceased
- 2000-12-04 CA CA002393809A patent/CA2393809C/en not_active Expired - Fee Related
- 2000-12-04 IL IL14947300A patent/IL149473A0/xx unknown
- 2000-12-04 EP EP00980930A patent/EP1237891B1/en not_active Expired - Lifetime
- 2000-12-04 MX MXPA02005533A patent/MXPA02005533A/es active IP Right Grant
- 2000-12-04 JP JP2001540986A patent/JP2004507442A/ja active Pending
- 2000-12-05 US US09/729,731 patent/US6706720B2/en not_active Expired - Lifetime
- 2000-12-06 PE PE2000001303A patent/PE20011029A1/es not_active Application Discontinuation
- 2000-12-06 AR ARP000106468A patent/AR029457A1/es unknown
- 2000-12-06 CO CO00092974A patent/CO5570109A1/es not_active Application Discontinuation
- 2000-12-07 UY UY26472A patent/UY26472A1/es not_active Application Discontinuation
2002
- 2002-05-05 IL IL149473A patent/IL149473A/en not_active IP Right Cessation
- 2002-06-05 NO NO20022649A patent/NO323588B1/no not_active IP Right Cessation
2003
- 2003-09-12 US US10/660,878 patent/US7157451B2/en not_active Expired - Lifetime
2006
- 2006-12-06 US US11/634,574 patent/US7541362B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
AR029457A1 (es)	2003-07-02
TWI291465B (en)	2007-12-21
ATE526329T1 (de)	2011-10-15
AU1812701A (en)	2001-06-12
IL149473A (en)	2009-05-04
RU2002118622A (ru)	2004-01-10
CA2393809C (en)	2009-11-17
PL364926A1 (en)	2004-12-27
MXPA02005533A (es)	2002-10-31
US6706720B2 (en)	2004-03-16
BR0016166A (pt)	2003-06-24
JP2004507442A (ja)	2004-03-11
CZ20021949A3 (cs)	2003-03-12
NZ518663A (en)	2004-11-26
EP1237891B1 (en)	2011-09-28
US20030022890A1 (en)	2003-01-30
MY125533A (en)	2006-08-30
HUP0301834A2 (hu)	2003-09-29
KR20020060255A (ko)	2002-07-16
NO20022649L (no)	2002-06-06
NO323588B1 (no)	2007-06-11
HK1048808A1 (zh)	2003-04-17
RU2296766C2 (ru)	2007-04-10
CN1407985A (zh)	2003-04-02
UY26472A1 (es)	2001-07-31
US7157451B2 (en)	2007-01-02
HUP0301834A3 (en)	2004-11-29
PE20011029A1 (es)	2001-12-02
EP1237891A1 (en)	2002-09-11
IL149473A0 (en)	2002-11-10
CA2393809A1 (en)	2001-06-07
WO2001040231A1 (en)	2001-06-07
US20040063687A1 (en)	2004-04-01
US7541362B2 (en)	2009-06-02
AU781862B2 (en)	2005-06-16
CO5570109A1 (es)	2005-10-31
US20070099899A1 (en)	2007-05-03

Publication	Publication Date	Title
NO20022649D0 (no)	2002-06-05	Heterocykliske dihydropyrimidiner som kaliumkanal inhibitorer
NO20014642D0 (no)	2001-09-25	Aminopyrimidiner som sorbitol-dehydrogenase-inhibitorer
DK2253620T3 (da)	2014-03-31	Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20021239D0 (no)	2002-03-13	Pteridinoner som kinase-inhibitorer
NO20022139L (no)	2002-05-03	Kinazolinderivater som VEGF inhibitorer
PT1181017E (pt)	2003-06-30	Inibidores de metaloproteases
NO20031006L (no)	2003-03-04	Imidazolo-5-yl-2-anilino-pyrimidiner som midler for inhibering av celleproliferasjon
DK1487805T3 (da)	2012-10-15	Pyrimidinderivater
NO20014483D0 (no)	2001-09-14	Aminderivater som proteaseinhibitorer
NO20015065L (no)	2001-10-18	Pyrazolobenzodiazepiner som CDK2-inhibitorer
DE60008527D1 (de)	2004-04-01	Zellproliferation inhibitoren
NO20024997D0 (no)	2002-10-17	2-guanidino-4-arylkinazoliner som NHE-3-inhibitorer
PT1194404E (pt)	2006-08-31	Inibidores de aspartil-protease
NO20050665L (no)	2005-04-18	Pyrrolidonderivater som MAOE inhibitoere
NO20016201D0 (no)	2001-12-18	Tienopyrimidiner som fosfodiesteraseinhibitorer
DK1228073T3 (da)	2003-11-03	Imidazolforbindelser som phosphodiesterase VII-inhibitorer
NO20021959L (no)	2002-05-29	Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer
NO20014875L (no)	2001-11-13	Promedikamenter for trombin inhibitorer
DE60024101D1 (de)	2005-12-22	Enzyminhibitoren
DK1147119T3 (da)	2004-01-19	2,3-O-isopropylidenderivater af monosaccharider som celleadhæsionsinhibitorer
IS7833A (is)	2005-05-02	Efnasambönd með sameinaða heteróhringi
DE60009260D1 (de)	2004-04-29	Thiopyranderivate as mmp-inhibitoren
DK1222193T3 (da)	2003-12-01	Imidazolderivater som phosphodiesterase VII-inhibitorer
NO20035206D0 (no)	2003-11-24	Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer
DK1487802T3 (da)	2011-04-04	2,3-diaryl-pyrazolidin-derivater som neurotensin-nedbrydende enzyminhibitorer

Legal Events

Date	Code	Title	Description
2012-07-23	MM1K	Lapsed by not paying the annual fees